Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading vertically integrated cannabis operator in the United States, today unveiled Curaleaf NANO Drops, a new addition to its lineup of products utilizing nanoemulsion technology. The Company, whose Select brand recently reached $1 million in sales in just one month in Florida, has launched a new precision-calibrated sublingual tincture which is infused with small, water-soluble cannabinoids, resulting in a faster, more efficient cannabinoid delivery system.
“Curaleaf NANO Drops are unique in their versatility and offer a great alternative for customers interested in a faster onset and more efficient dosing product,” said Joe Bayern, President of Curaleaf. “After the successful launch of Curaleaf Sublingual Tablets, we are excited to expand our portfolio of products utilizing this technology to bring customers more options when it comes to their cannabis choices.”
Unlike oil-based medium-chain triglyceride (MCT) tinctures, Curaleaf NANO Drops are formulated to immediately dissolve directly in the mouth. The science behind Curaleaf NANO Drops is a major upgrade to traditional MCT’s, as they deliver a faster onset and shorter duration due to the water-soluble nature of the technology. Curaleaf NANO Drops join the Company’s first to Florida market Sublingual Tablets, providing patients another way to confidently manage their treatment plan.
Curaleaf NANO Drops are available in a slim 30ML tincture bottle and deliver a precise 5MG THC dose per 1ML drop. Drops are available unflavored or in lime or grapefruit varieties. The tincture is the second product Curaleaf has developed using its cutting-edge NANO technology; earlier this year the company introduced Curaleaf and Select NANO Gummies in five other states including Arizona, California, Maine, Massachusetts, and Nevada. Curaleaf NANO Drops will be available exclusively at all Curaleaf Florida locations at launch, with plans to expand to other states.
About Curaleaf Holdings, Inc.
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading vertically integrated U.S. multi-state cannabis operator with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. Curaleaf currently operates in 23 states with 93 dispensaries, 22 cultivation sites and over 30 processing sites, and employs over 3,000 team members across the United States. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information please visit www.curaleaf.com.